- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07677280
A Consumer Use Behavior Study to Measure the Puffing Topography of Heated Tobacco Products
A Consumer Use Behavior Study to Measure the Puffing Topography of Heated Tobacco Products (Glo and Glo Plus)
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Montgomery Hedgecock
- Telefoonnummer: 336-741-3761
- E-mail: montgomery_hedgecock@rjrt.com
Studie Locaties
-
-
-
Cheshunt, Verenigd Koninkrijk
- Cheshunt Community Sports Park
-
Sheffield, Verenigd Koninkrijk
- Channing Hall
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Ability to read, understand, and be willing to sign an ICF and complete questionnaires written in English.
- Generally healthy male or female, between age 21-65 years (inclusive at the time of consent), verified with government-issued identification.
- All female (assigned at birth) candidate participants and those who identify as "intersex" or "unknown" during screening who agree to take the pregnancy test on site and receive a negative result, and who affirm at the SEV that they are not pregnant or intending to become pregnant.
- Self-report currently smoking at least five CPD on smoking days in the past 30 days.
- Smoke CC on at least 27 days out of last 30 days.
- Have smoked at least 100 factory-made filtered CC in their lifetime prior to SEV.
- Indicate a willingness to use an HTP.
- Agree to participate in the study and to abide by the study restrictions and requirements, including the use of the assigned Study IP, as described in the ICF.
- Agree not to allow any other person to use any product provided to them for use during this study.
Exclusion Criteria:
- Female participants who self-report they are pregnant or breastfeeding or could become pregnant or start breastfeeding in the next 6 months from the study start date.
Women who self-report they are not intending to use adequate contraception methods to prevent pregnancy.
a) Examples of acceptable contraception methods are, but not limited to: i. Surgical sterilization (hysterectomy, bilateral tubal ligation/occlusion, bilateral oophorectomy, bilateral salpingectomy); ii. Established use of oral, implantable, injectable, or transdermal methods of contraception associated with inhibition of ovulation; iii. Physical barrier method (e.g., condom, diaphragm/sponge/cervical cap) with spermicide; iv. Non-hormone releasing intrauterine devices (IUD) or hormone-releasing IUDs (e.g., Mirena or Kyleena); v. Vasectomized partner; vi. Abstinence from heterosexual intercourse (as a lifestyle choice, not just for the purpose of study participation); and vii. Post-menopausal who are not on hormone replacement therapy.
- Males who self-report they are not willing to use a barrier method of contraception (e.g., a condom with spermicide) or to refrain from donating sperm from the time of signing the informed consent until the EOS, unless they have undergone a vasectomy or were abstinent from heterosexual intercourse, or their female partner was not able to bear children.
- Individuals who self-report having pacemakers or other embedded electronic medical devices.
- Individuals who self-report having an unstable heart condition, severe hypertension or diabetes.
- Individuals who self-report they are sensitive to nicotine.
- Individuals who respond with 'Poor' or 'Don't know' to general physical or mental health.
- Individuals who have used a nicotine replacement therapy (NRT) product or a prescription drug to help stop smoking (e.g., varenicline, bupropion) in the past 30 days.
- Individuals who are employed by a company that manufactures tobacco, HTPs, marketing or in ongoing litigation with a tobacco company.
- Individuals who self-report that they are planning to quit all nicotine products in the next three months.
- Individuals who are personally, have household members, or have close family or friends in ongoing or past litigation with a company that manufactures tobacco or HTPs.
- People who have taken part in a tobacco/nicotine research study in the past 30 days.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ander
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: HTP Device 1
|
Tobacco Flavor
Menthol Flavor
|
|
Experimenteel: HTP Device 2
|
Tobacco Flavor
Menthol Flavor
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
To measure the puffing topography of primary CC smokers when using either the glo or glo plus device with one of two stick variants during a five-day use period.
Tijdsspanne: 5 days
|
The primary endpoints of this study will be measured in using built-in topography measures and the product use behavior (PUB) instrument (Study Arm 1 only). The data will include:
|
5 days
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Determine the frequency of use of the glo and glo plus devices in Standard and Boost Mode
Tijdsspanne: 5 days
|
This secondary endpoint will be measured using the built-in topography measures through the Product Use Behavior (PUB) device
|
5 days
|
|
Determine the frequency of use of the glo plus pen detached from the charger pack (Study Arm 2 only)
Tijdsspanne: 5 days
|
This secondary endpoint will be measured using the built-in topography measures through the Product Use Behavior (PUB) device
|
5 days
|
|
Determine the average daily consumption (ADC) of CC smoked, sticks consumed, and other TNPs used
Tijdsspanne: 5 days
|
Through self-reported questionnaires
|
5 days
|
|
Determine overall product liking and purchase intent
Tijdsspanne: 5 days
|
Overall Product Liking: 1 (Strongly Dislike) - 10 (Strongly Like) Purchase Intent: 1 (Definitely would not purchase) - 10 (Definitely would purchase)
|
5 days
|
|
Characterize demographic characteristics
Tijdsspanne: 5 days
|
5 days
|
|
|
Determine the safety profile (i.e., adverse events/experiences [AEs]) of the Study IP
Tijdsspanne: 5 days
|
5 days
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie directeur: Melissa Tapia, Ph.D., RAIS Company
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- PHI252503
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .